Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2020 · 10-Q
Revenue$8.78M$8.78M+25.4% vs Q2 2019 Net Income-$1.08M-$1.08MN/M vs Q2 2019 EPS Diluted-$0.07-$0.07N/M vs Q2 2019 Gross Profit$5,144,214+19.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$127,643N/M Free Cash Flowderived$118,582N/M Margins · derivedGross margin58.6%−3.1 pt vs Q2 2019
Operating margin-12.0%−18.9 pt vs Q2 2019
Net margin-12.3%−18.1 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 5, 2020 · 36 d after period end